id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0874-0065,FDA,FDA-2021-N-0874,REDACTED CDER_Proposed Order FDA-2021-N-0874,Other,Memo,2022-10-13T04:00:00Z,2022,10,2022-10-13T04:00:00Z,,2022-10-13T18:09:33Z,,0,0,0900006485401637
FDA-2021-N-0874-0064,FDA,FDA-2021-N-0874,"Letter from Hogan Lovells US LLP (Intarcia Therapeutics, Inc.)",Other,Letter(s),2022-10-11T04:00:00Z,2022,10,2022-10-11T04:00:00Z,,2022-10-11T16:50:14Z,,0,0,09000064853e869c
FDA-2021-N-0874-0063,FDA,FDA-2021-N-0874,Letter from Hogan Lovells LLP (Intarcia),Other,Letter(s),2022-09-13T04:00:00Z,2022,9,2022-09-13T04:00:00Z,,2022-09-13T18:40:16Z,,0,0,09000064852d546c
FDA-2021-N-0874-0062,FDA,FDA-2021-N-0874,Letter from Lunenfeld-Tanenbaum Research Institute to FDA CDER,Other,Letter(s),2022-09-09T04:00:00Z,2022,9,2022-09-09T04:00:00Z,,2022-09-09T16:08:46Z,,0,0,09000064852dabc1
FDA-2021-N-0874-0061,FDA,FDA-2021-N-0874,Response to Intarcia Counsel 8 26 22,Other,Agency Response,2022-08-26T04:00:00Z,2022,8,2022-08-26T04:00:00Z,,2022-08-26T18:32:47Z,,0,0,090000648527b72a
FDA-2021-N-0874-0059,FDA,FDA-2021-N-0874,Letter to Matthew Warren from FDA CDER,Other,Letter(s),2022-07-27T04:00:00Z,2022,7,2022-07-27T04:00:00Z,,2022-07-27T20:34:09Z,,0,0,09000064851ee675
FDA-2021-N-0874-0058,FDA,FDA-2021-N-0874,OCC Separation of Functions Memo Intarcia,Other,Letter(s),2022-04-29T04:00:00Z,2022,4,2022-04-29T04:00:00Z,,2022-04-29T18:01:52Z,,0,0,090000648504421f
FDA-2021-N-0874-0057,FDA,FDA-2021-N-0874,Intarcia Letter April 15 22,Other,Letter(s),2022-04-18T04:00:00Z,2022,4,2022-04-18T04:00:00Z,,2022-04-18T18:45:57Z,,0,0,0900006485020cf6
FDA-2021-N-0874-0056,FDA,FDA-2021-N-0874,Letter from Hogan Lovells US LLP to Office of the Commissioner,Other,Letter(s),2022-03-25T04:00:00Z,2022,3,2022-03-25T04:00:00Z,,2022-03-25T15:46:13Z,,0,0,0900006484fd6e37
FDA-2021-N-0874-0055,FDA,FDA-2021-N-0874,"Intarcia Therapeutics, Inc. Hearing Request for NDA 209053 ITCA 650 (exenatide in DUROS device)",Other,Letter(s),2022-03-24T04:00:00Z,2022,3,2022-03-24T04:00:00Z,,2022-03-24T14:27:29Z,,0,0,0900006484fde8d1
FDA-2021-N-0874-0054,FDA,FDA-2021-N-0874,"Intarcia Therapeutics, Inc. Hearing Request for NDA 209053 ITCA 650 (exenatide) implant",Other,Letter(s),2022-03-01T05:00:00Z,2022,3,2022-03-01T05:00:00Z,,2022-03-01T19:22:01Z,,0,0,0900006484fb4468
FDA-2021-N-0874-0053,FDA,FDA-2021-N-0874,Supplement from Hogan Lovells US LLP,Other,Supplement (SUP),2022-02-17T05:00:00Z,2022,2,2022-02-17T05:00:00Z,,2022-02-19T02:00:27Z,,0,0,0900006484f7e6ae